Advertisement


Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane

2016 Gastrointestinal Cancers Symposium

Advertisement

Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (Abstract 5).



Related Videos

Solid Tumors

Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).

Gastroesophageal Cancer

Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial

Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).

Gastroesophageal Cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).

Colorectal Cancer

Daniel G. Haller, MD, on Colon and Rectal Cancers: A Global Overview

Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.

Colorectal Cancer

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study (German Language Version)

Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493).

Advertisement

Advertisement



Advertisement